Abstract
At present there is controversy over the addition of unconjugated estriol to maternal serum screening for trisomy 21. To resolve the controversy, we posed the hypothesis that there is no difference in sensitivity or specificity between a triple screen (α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol) and a double screen (α-fetoprotein and human chorionic gonadotropin) in detecting a fetus with Down's syndrome. To test the hypotheses we conducted an analysis of prospective studies in the available literature. This technique was used because the occurrence of trisomy 21 is a rare event in pregnancy, making it difficult to arrive at a definitive conclusion on the basis of a single study. Using the statistical technique of meta-analysis, we have determined that the addition of unconjugated estriol does improve the detection of trisomy 21.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 176-181 |
| Number of pages | 6 |
| Journal | Clinical Laboratory Management Review |
| Volume | 10 |
| Issue number | 2 |
| State | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Leadership and Management
Cite this
Does the addition of unconjugated estriol in maternal serum screening improve the detection of trisomy 21? A meta-analysis. / Smith, E. R.; Petersen, J.; Okorodudu, Anthony; Bissell, M. G.
In: Clinical Laboratory Management Review, Vol. 10, No. 2, 1996, p. 176-181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Does the addition of unconjugated estriol in maternal serum screening improve the detection of trisomy 21? A meta-analysis
AU - Smith, E. R.
AU - Petersen, J.
AU - Okorodudu, Anthony
AU - Bissell, M. G.
PY - 1996
Y1 - 1996
N2 - At present there is controversy over the addition of unconjugated estriol to maternal serum screening for trisomy 21. To resolve the controversy, we posed the hypothesis that there is no difference in sensitivity or specificity between a triple screen (α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol) and a double screen (α-fetoprotein and human chorionic gonadotropin) in detecting a fetus with Down's syndrome. To test the hypotheses we conducted an analysis of prospective studies in the available literature. This technique was used because the occurrence of trisomy 21 is a rare event in pregnancy, making it difficult to arrive at a definitive conclusion on the basis of a single study. Using the statistical technique of meta-analysis, we have determined that the addition of unconjugated estriol does improve the detection of trisomy 21.
AB - At present there is controversy over the addition of unconjugated estriol to maternal serum screening for trisomy 21. To resolve the controversy, we posed the hypothesis that there is no difference in sensitivity or specificity between a triple screen (α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol) and a double screen (α-fetoprotein and human chorionic gonadotropin) in detecting a fetus with Down's syndrome. To test the hypotheses we conducted an analysis of prospective studies in the available literature. This technique was used because the occurrence of trisomy 21 is a rare event in pregnancy, making it difficult to arrive at a definitive conclusion on the basis of a single study. Using the statistical technique of meta-analysis, we have determined that the addition of unconjugated estriol does improve the detection of trisomy 21.
UR - http://www.scopus.com/inward/record.url?scp=0030001681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030001681&partnerID=8YFLogxK
M3 - Article
VL - 10
SP - 176
EP - 181
JO - Clinical laboratory management review : official publication of the Clinical Laboratory Management Association / CLMA
JF - Clinical laboratory management review : official publication of the Clinical Laboratory Management Association / CLMA
SN - 0888-7950
IS - 2
ER -